Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Fareed Moses Collado

Interventional Cardiology Chicago, IL Medical Doctor

NPI 1275763708 CMS profile 1026825

1725 W Harrison St Ste 1159, Chicago, IL 60612

Open in the dashboard

General payments

$42,133

154 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$235,892 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Fareed Moses Collado of Chicago, IL is reported in the CMS Open Payments database as having received $42,133 across 154 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $235,892 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 85th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,492 51
2024 General $2,668 27
2023 General $814 12
2022 General $9,343 17
2021 General $10,539 31
2020 General $9,144 14
2019 General $134 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fareed Moses Collado
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Fareed Moses Collado were reported at $9,492. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Fareed Moses Collado Interventional Cardiology median Middle half National median
2019 $134 $1,097 $329–$3,048 $163
2020 $9,144 $473 $161–$1,480 $114
2021 $10,539 $677 $233–$1,827 $132
2022 $9,343 $978 $333–$2,724 $149
2023 $814 $1,136 $382–$2,986 $160
2024 $2,668 $1,181 $395–$3,326 $164
2025 $9,492 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $24,771 11 payments
  2. Abbott Laboratories $10,288 56 payments
  3. Edwards Lifesciences Corporation $4,571 36 payments
  4. Medtronic, Inc. $1,239 20 payments
  5. Boston Scientific Corporation $471 13 payments
  6. Abiomed $310 6 payments
  7. Eisai Inc. $125 1 payment
  8. Teleflex LLC $63 2 payments
  9. Medtronic Vascular, Inc. $61 1 payment
  10. Shockwave Medical, Inc $61 2 payments
  11. Other $173 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $27,213 11 payments
  2. Food and Beverage $7,795 116 payments
  3. Travel and Lodging $5,103 24 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $2,000 2 payments
  5. Entertainment $23 1 payment
Products named General payments · program years 2019–2025
  1. Carto 3 $16,259 7 payments
  2. Carto 3 System $8,513 4 payments
  3. TRICLIP $2,938 17 payments
  4. COROFLOW $2,835 8 payments
  5. DRAGONFLY OPSTAR $2,000 2 payments
  6. EVOQUE $1,647 13 payments
  7. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,523 7 payments
  8. AMPLATZER Occluders $735 9 payments
  9. MitraClip System $725 5 payments
  10. COREVALVE EVOLUT R $594 10 payments
  11. Other $3,769 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,063

Prescriptions dispensed, refills included

Drug cost

$153,537

Paid at the pharmacy, in all

Branded share of claims

20.1%

Brand-name drugs, not generics

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 62 $57,363
Jardiance Empagliflozin Brand 26 $32,970
Xarelto Rivaroxaban Brand 26 $30,695
Entresto Sacubitril/Valsartan Brand 20 $19,095
Ranolazine Er Ranolazine Brand 13 $1,912
Metoprolol Succinate Generic 108 $1,708
Bumetanide Generic 20 $1,267
Atorvastatin Calcium Generic 150 $1,190
Ezetimibe Generic 33 $1,031
Carvedilol Generic 82 $831

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$130,821

Medicare's payments for the services billed

Medicare patients

395

Average age 75

Services billed

965

186 women, 209 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 61%
Arthritis 54%
Diabetes 53%
Chronic kidney disease 49%
Atrial fibrillation 48%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record